We are live on ! Find out more
ARTV

Artiva Biotherapeutics
ARTV

34 hedge funds and large institutions have $72.7M invested in Artiva Biotherapeutics in 2025 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 15 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

40% more capital invested

Capital invested by funds: $52.1M → $72.7M (+$20.6M)

5.24% less ownership

Funds ownership: 74.32% → 69.08% (-5.2%)

15% less funds holding

Funds holding: 40 → 34 (-6)

50% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 12

73% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 15

Holders
34
Holders Change
-6
Holders Change %
-15%
% of All Funds
0.41%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.02%
New
6
Increased
4
Reduced
15
Closed
12
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Two Sigma Investments
Two Sigma Investments
New York
+$470K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$328K
3
Marshall Wace
Marshall Wace
United Kingdom
+$300K
4
Jane Street
Jane Street
New York
+$154K
5
Renaissance Technologies
Renaissance Technologies
New York
+$140K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$2.29M
2
VP
venBio Partners
California
-$1.89M
3
BNP Paribas Financial Markets
BNP Paribas Financial Markets
France
-$446K
4
BlackRock
BlackRock
New York
-$309K
5
Citigroup
Citigroup
New York
-$303K
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
26
Fidelity Investments
Massachusetts
$15.3K -$5.14K -1,362 -28%
Wells Fargo
27
Wells Fargo
California
$6.43K -$755 -200 -12%
TRCT
28
Tower Research Capital (TRC)
New York
$4.73K -$33.5K -8,878 -89%
BNP Paribas Financial Markets
29
BNP Paribas Financial Markets
France
$2.33K -$446K -118,005 -100%
MSFP
30
Mark Sheptoff Financial Planning
Connecticut
$1.72K – – –
Royal Bank of Canada
31
Royal Bank of Canada
Ontario, Canada
$1K -$1.89K -501 -60%
JP Morgan Chase
32
JP Morgan Chase
New York
$802 -$14.4K -3,815 -95%
Bank of America
33
Bank of America
North Carolina
$484 -$60.6K -16,032 -99%
Osaic Holdings
34
Osaic Holdings
Arizona
$137 +$121 +32 New
Citadel Advisors
35
Citadel Advisors
Florida
– -$2.29M -798,397 Closed
Citigroup
36
Citigroup
New York
– -$303K -105,573 Closed
XT
37
XTX Topco
Cayman Islands
– -$138K -47,973 Closed
LCM
38
Landscape Capital Management
New Jersey
– -$112K -39,133 Closed
HF
39
HRT Financial
New York
– -$77K -26,953 Closed
Qube Research & Technologies (QRT)
40
Qube Research & Technologies (QRT)
United Kingdom
– -$73.3K -25,552 Closed
Barclays
41
Barclays
United Kingdom
– -$36.4K -12,696 Closed
CUAMC
42
China Universal Asset Management Company
China
– -$12.3K -4,281 Closed
Mirae Asset Global Investments
43
Mirae Asset Global Investments
South Korea
– -$2.71K -944 Closed
GFM
44
GF Fund Management
China
– -$1.46K -510 Closed
EWA
45
EverSource Wealth Advisors
Alabama
– -$456 -159 Closed
1
2

ARTV Hedge Fund Activity: Q4 2025 in Review

34 of the 8,228 institutional investors tracked by Wall St. Rank reported a position in Artiva Biotherapeutics (ARTV) for Q4 2025, worth a combined $72.7M — up 40% from $52.1M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of ARTV and 6 opened new positions — a net loss of 6 holders — while 15 trimmed existing stakes and 4 added.

The largest buyer was Two Sigma Investments, adding an estimated $470K. The largest seller was Citadel Advisors, exiting entirely with an estimated $2.29M sold.

  • 34 institutional investors held Artiva Biotherapeutics (ARTV) as of Q4 2025, down from 40 in Q3 2025.
  • Funds reported $72.7M of Artiva Biotherapeutics stock for Q4 2025, up 40% quarter-over-quarter.
  • 6 funds opened new Artiva Biotherapeutics positions in Q4 2025 and 12 closed out, a net change of -6 holders.
  • The largest Artiva Biotherapeutics buyer in Q4 2025 was Two Sigma Investments, an estimated $470K added.
  • The largest Artiva Biotherapeutics seller in Q4 2025 was Citadel Advisors, an estimated $2.29M sold.

Based on aggregated 13F filings for Q4 2025.